Merck & Co., Inc.'s Stock Analysis

Merck Shareholders Vote on Six Proposals at Annual Meeting

Merck & Co., Inc. held its Annual Meeting of Shareholders on May 26, 2026. During the meeting, shareholders voted on six proposals, with a majority required for approval of each proposal.

May 28, 2026 16:15:25

Merck Co Closes $5 Billion Public Offering of Notes

On May 22, 2026, Merck & Co., Inc. completed a public offering totaling $5 billion in various notes. This includes $500 million in Floating Rate Notes due 2028, $1 billion in 4.300% Notes due 2028, $500 million in 4.650% Notes due 2031, $1 billion in 4.950% Notes due 2033, $1.5 billion in 5.200% Notes due 2036, $500 million in 5.750% Notes due 2046, and $1 billion in 5.850% Notes due 2056. The offering was conducted under the company's Registration Statement on Form S-3ASR, originally filed in March 2024.

The notes are issued under an indenture dated January 6, 2010, with U.S. Bank Trust National Association serving as trustee. Detailed documentation related to the notes, including officers' certificates and a legal opinion, has been incorporated by reference in the filing. This capital raise may impact the company’s financial flexibility and liquidity in the coming years.

May 22, 2026 16:21:18

Merck Reports First Quarter 2026 Financial Results and Losses

Merck & Co., Inc. announced its financial results for the first quarter of 2026, reporting a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28. The losses were primarily attributed to a $3.62 per share charge related to the acquisition of Cidara Therapeutics. The company's revenue was driven by strong sales in oncology and animal health, but overall gross margin decreased to 74.2% from 78.0% in the previous year, largely due to increased amortization and restructuring costs.

The company also highlighted several significant regulatory approvals and clinical milestones, including the FDA approval of IDVYNSO for HIV treatment. Merck anticipates full-year 2026 sales between $65.8 billion and $67.0 billion, with a non-GAAP effective income tax rate projected between 23.5% and 24.5%. Additionally, the company is planning a tender offer to acquire Terns, which is expected to incur a one-time charge of approximately $5.8 billion. The company will hold an Oncology Investor Event on June 1, 2026, to provide updates on its oncology strategy.

Apr 30, 2026 06:53:18

Merck Reports 2025 Financial Results and Strategic Developments

Merck & Co. announced its financial results for the fourth quarter and full year of 2025, reporting a GAAP earnings per share (EPS) of $1.19 for Q4 and $7.28 for the year. Non-GAAP EPS was $2.04 for the fourth quarter and $8.98 for the full year. The company experienced growth in its pharmaceutical sales, which reached $58.1 billion, driven by strong performances in oncology and new product launches, although this was partially offset by declines in the vaccines and immunology franchises. Additionally, animal health sales grew by 8% to $6.4 billion, supported by livestock product performance and new launches in companion animals.

Merck also highlighted significant advancements in its product pipeline, with positive results from 18 Phase 3 trials and 80 ongoing studies. The company entered an agreement with the U.S. government aimed at reducing medicine costs, ensuring access to affordable medications for Americans. Furthermore, Merck plans to invest over $70 billion in capital and R&D to enhance U.S. production and innovation. For 2026, the company anticipates sales between $65.5 billion and $67.0 billion, including a one-time charge related to the acquisition of Cidara Therapeutics.

Feb 03, 2026 06:38:40

Merck Co Completes $5.75 Billion Public Offering of Notes

Merck & Co., Inc. has successfully closed an underwritten public offering totaling $5.75 billion in various series of notes. This includes $500 million in Floating Rate Notes maturing in 2029, alongside other notes with fixed interest rates due between 2029 and 2065, with amounts ranging from $750 million to $1.5 billion for each series.

The notes are issued under a previously filed registration statement and governed by an indenture established in 2010. The offering aims to raise capital through these debt instruments, which may impact the company's financial position and liquidity.

Dec 04, 2025 16:36:38

Merck Reports Third Quarter 2025 Financial Results and Updates

Merck & Co., Inc. announced its financial results for the third quarter of 2025, reporting a GAAP earnings per share (EPS) of $2.32 and a non-GAAP EPS of $2.58. The results reflect a significant increase compared to the previous year, primarily due to lower charges related to acquisitions and development milestones. Notably, sales from the company's Koselugo product saw a substantial increase, rising to $214 million, attributed to a revised collaboration agreement with AstraZeneca. Overall, the company's gross margin improved to 77.7%, and R&D expenses decreased by 28% compared to the same quarter in 2024, indicating a shift in spending priorities within the company’s operational strategies.

Merck also highlighted advancements in its product pipeline, including FDA approvals for KEYTRUDA QLEX for various cancer treatments and significant investments in U.S. manufacturing and R&D, totaling over $70 billion planned for expansion starting in 2025. The company is set to host an investor event during the American Heart Association Scientific Sessions in November 2025, where it will present new data from its cardiovascular portfolio. For the full year 2025, Merck projects sales between $64.5 billion and $65.0 billion, with a non-GAAP EPS expectation of $8.93 to $8.98, reflecting operational improvements and strategic adjustments.

Oct 30, 2025 06:40:38

Merck Issues $5 Billion in New Debt Securities

Merck & Co., Inc. completed a public offering of $5 billion in various debt securities, including Floating Rate Notes and other fixed-rate notes, with maturities ranging from 2027 to 2055. The offering included $500 million of Floating Rate Notes, $750 million of 3.850% Notes due 2027, $750 million of 4.150% Notes due 2030, $1 billion of 4.550% Notes due 2032, $1.75 billion of 4.950% Notes due 2035, and $1.25 billion of 5.700% Notes due 2055.

The debt securities were issued under an existing indenture and are part of the company's strategy to manage its capital structure. The legal and procedural documentation related to the offering has been filed with the Securities and Exchange Commission, ensuring compliance with regulatory requirements.

Sep 09, 2025 16:33:09

Merck Announces Restructuring Program and Financial Results for Q2 2025

Merck & Co. reported its financial results for the second quarter of 2025, with GAAP earnings per share (EPS) at $1.76, a decrease from $2.14 in the same quarter of 2024. The company recorded a gross margin of 77.5%, up from 76.8% year-over-year, largely due to a favorable product mix. Research and development expenses increased by 16% to $4.0 billion, influenced by a $200 million upfront payment for a license agreement with Jiangsu Hengrui Pharmaceuticals. Non-GAAP EPS was $2.13, down from $2.28, reflecting higher operating expenses and unfavorable foreign exchange impacts. Additionally, Merck announced a planned acquisition of Verona Pharma for approximately $10 billion, expected to close in Q4 2025, which adds to its cardio-pulmonary pipeline.

As part of a new multiyear optimization initiative, Merck approved a restructuring program aimed at generating $3.0 billion in annual cost savings by the end of 2027. This program will involve eliminating certain administrative, sales, and research positions while continuing to hire in strategic growth areas. The anticipated pretax costs for the restructuring are estimated at $3.0 billion, with approximately 60% expected to be cash-related. The initiative is designed to redirect resources toward new product launches and enhance the company's pipeline across various therapeutic areas.

Jul 29, 2025 06:42:43

Merck Reports Q1 2025 Earnings and Pipeline Developments

Merck announced its financial results for the first quarter of 2025, reporting a GAAP earnings per share (EPS) of $2.01 and a non-GAAP EPS of $2.22. The increase in EPS compared to the first quarter of 2024 was primarily due to a previous charge related to the acquisition of Harpoon Therapeutics. The company noted a gross margin of 78.0%, an increase from the previous year, attributed to product mix and lower restructuring costs, despite higher amortization and foreign exchange impacts. Research and development expenses decreased by 9% year-over-year, largely due to a significant charge in the prior year, although new costs were incurred for milestone achievements and increased clinical development activities.

In addition to financial results, Merck highlighted advancements in its pipeline, including key regulatory milestones for several products in oncology and vaccines. Notable developments include the submission of applications for subcutaneous pembrolizumab and the initiation of a Phase 3 trial for an investigational treatment for diffuse large B-cell lymphoma. The company also received various approvals for its vaccines in Europe and China. Merck plans to invest significantly in U.S. manufacturing and R&D, with over $12 billion allocated since 2018 and expectations for additional investment by 2028. The company updated its full-year 2025 sales outlook to between $64.1 billion and $65.6 billion, factoring in the impact of tariffs and foreign exchange.

Apr 24, 2025 06:45:16

Merck Reports $57.4 Billion in Pharmaceutical Sales for 2024

Merck reported a 7% increase in pharmaceutical sales for 2024, reaching $57.4 billion, driven by strong demand for products like KEYTRUDA and the successful launch of WINREVAIR. The company's gross margin improved to 76.3% for the year, aided by a favorable product mix and foreign exchange effects. Additionally, Merck's non-GAAP earnings per share rose significantly to $7.65, compared to $1.51 in 2023, reflecting operational strength and reduced charges from business development activities.

However, Merck faced challenges with lower sales in certain areas, including JANUVIA and LAGEVRIO, primarily due to pricing pressures and generic competition. The company also reported a decline in research and development expenses, down 41% for the full year, which could impact future innovation. Furthermore, the effective tax rates were influenced by reductions in reserves for unrecognized income tax benefits, which may not be sustainable in the long term.

Feb 04, 2025 06:45:47